Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Actinium Pharmaceuticals (ATNM) Interest & Investment Income (2023 - 2025)

Actinium Pharmaceuticals (ATNM) has disclosed Interest & Investment Income for 2 consecutive years, with $853000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Interest & Investment Income fell 16.29% to $853000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $3.9 million, a N/A change, with the full-year FY2024 number at $3.9 million, up 25.02% from a year prior.
  • Interest & Investment Income was $853000.0 for Q4 2024 at Actinium Pharmaceuticals, down from $1.0 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $1.1 million in Q3 2023 to a low of $853000.0 in Q4 2024.